<DOC>
	<DOC>NCT00694980</DOC>
	<brief_summary>This is a randomized , double-blind, placebo-controlled study of approximately 70 patients with ulcerative colitis.</brief_summary>
	<brief_title>A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Able and willing to provide written informed consent 1870 years of age Males and females with reproductive potential: Willing to use a reliable method of contraception Diagnosis of ulcerative colitis Eligible to receive biologic therapy Disease duration of &gt;=12 weeks Requirement for hospitalization due to severity of ulcerative colitis Moderate to severe anemia Any manifestation of ulcerative colitis or other conditions likely to require, in the investigator's judgment, treatment with &gt;20 mg/day of prednisone, or prednisone equivalent, during the course of the study Pregnant or lactating Lack of peripheral venous access Inability to comply with study protocol History or presence of contraindicated diseases Congenital immune deficiency Active or prior infection with HIV or hepatitis B or C History of severe systemic bacterial, fungal, viral, or parasitic infections History of any other opportunistic infections within 12 weeks prior to initiation of study treatment Received a live attenuated vaccine within 4 weeks prior to screening Hospitalized within 4 weeks prior to screening Received any contraindicated therapy within 12 weeks prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>UC</keyword>
	<keyword>Ulcerative Colitis</keyword>
</DOC>